

DAFTAR PUSTAKA

1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. *Diabetes Res Clin Pract* [Internet]. 2018;138:271–81. Available from: <https://doi.org/10.1016/j.diabres.2018.02.023> doi: 10.1016/j.diabres.2018.02.023
2. Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: Current situation and perspectives. *Eur J Prev Cardiol*. 2019;26(2_suppl):7–14. <https://doi.org/10.1177/2047487319881021>
3. International Diabetes Federation. *IDF Diabetes Atlas*. 9th ed. Brussels, Belgium: International Diabetes Federation; 2019.
4. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017. *Cardiovasc Diabetol* [Internet]. 2018;17(1):1–19. Available from: <https://doi.org/10.1186/s12933-018-0728-6> doi: 10.1186/s12933-018-0728-6
5. Singh GM, Danaei G, Farzadfar F, Stevens GA, Woodward M, Wormser D, et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: A pooled analysis. *PLoS One*. 2013;8(7). <https://doi.org/10.1371/journal.pone.0065174>
6. Pan W, Lu H, Lian B, Liao P, Guo L, Zhang M. Prognostic value of HbA1c for in - hospital and short - term mortality in patients with acute coronary syndrome : a systematic review and meta - analysis. *Cardiovasc Diabetol* [Internet]. 2019;1–12. Available from: <https://doi.org/10.1186/s12933-019-0970-6> doi: 10.1186/s12933-019-0970-6



mstrong EJ, Rutledge JC, Rogers JH. Coronary Artery Revascularization Patients with Diabetes. *Circ J* [Internet]. 2013;128(5):1–22. Available from:

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf> doi: 10.1161/CIRCULATIONAHA.113.002114. Coronary

8. Association AD. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. *Diabetes Care*. 2021;44(January):S15–33. <https://doi.org/10.2337/dc21-S002>
 9. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. 2002;342:1–5.
 10. Almdal T, Scharling H, Jensen JS, Vestergaard H. The Independent Effect of Type 2 Diabetes Mellitus on Ischemic Heart Disease, Stroke, and Death. *Arch Intern Med*. 2004;164(13):1422. <https://doi.org/10.1001/archinte.164.13.1422>
 11. Sala J, Masiá R, González de Molina FJ, Fernández-Real JM, Gil M, Bosch D, et al. Short-term mortality of myocardial infarction patients with diabetes or hyperglycaemia during admission. *J Epidemiol Community Health*. 2002;56(9):707–12. <https://doi.org/10.1136/jech.56.9.707>
 12. Jelesoff NE, Feinglos M, Granger CB, Califf RM. Outcomes of diabetic patients following acute myocardial infarction: A review of the major thrombolytic trials. *Eur J Cardiovasc Prev Rehabil*. 1997;4(2):100–11. <https://doi.org/10.1177/174182679700400206>
 13. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes: UKPDS 66. *Diabetes Care*. 2004;27(1):201–7. <https://doi.org/10.2337/diacare.27.1.201>
 14. PERKENI. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021 [Internet]. Perhimpunan Endokrinologi Indonesia. 2021. 46 p. Available from: www.ginasthma.org.
 15. Decroli E. DIABETES MELLITUS TIPE 2. Kam A, Decroli GP, Rahmadi editors. Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas; 2019.
- Centers for Disease Control and Prevention. National Diabetes Statistics



Report. 2022.

17. Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB, et al. A Unified Pathophysiological Construct of Diabetes and its Complications. *Trends Endocrinol Metab.* 2017;28(9):645–55. <https://doi.org/10.1016/j.tem.2017.05.005>
18. Akalu Y, Belsti Y. Hypertension and its associated factors among type 2 diabetes mellitus patients at Debre Tabor general hospital, northwest Ethiopia. *Diabetes, Metab Syndr Obes.* 2020;13:1621–31. <https://doi.org/10.2147/DMSO.S254537>
19. Patoulis D, Papadopoulou C, Stavropoulos K, Zografou I, Doumas M, Karagiannis A. Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors. *J Clin Hypertens.* 2020;22(4):562–71. <https://doi.org/10.1111/jch.13831>
20. PERHIMPUNAN DOKTER SPESIALIS KARDIOVASKULAR INDONESIA. PEDOMAN TATALAKSANA SINDROM KORONER AKUT. 4th ed. Jakarta: PERHIMPUNAN DOKTER SPESIALIS KARDIOVASKULAR INDONESIA; 2018.
21. Salari N, Morddarvanjoghi F, Abdolmaleki A, Rasoulpoor S, Khaleghi AA, Hezarkhani LA, et al. The global prevalence of myocardial infarction : a systematic review and meta - analysis. *BMC Cardiovasc Disord* [Internet]. 2023;1–12. Available from: <https://doi.org/10.1186/s12872-023-03231-w>
doi: 10.1186/s12872-023-03231-w
22. KEMENTERIAN KESEHATAN REPUBLIK INDONESIA. HASIL RISET KESEHATAN DASAR (RISKESDAS) 2018. Jakarta; 2018.
23. Babes EE, Bustea C, Behl T, Abdel-Daim MM, Nechifor AC, Stoicescu M, et al. Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy. *Biomed Pharmacother* [Internet]. 2022;148(February):112772. Available from: <https://doi.org/10.1016/j.biopha.2022.112772>
doi: 10.1016/j.biopha.2022.112772



24. Knapp M, Tu X, Wu R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy. *Acta Pharmacol Sin* [Internet]. 2019;40(1):1–8. Available from: <http://dx.doi.org/10.1038/s41401-018-0042-6> doi: 10.1038/s41401-018-0042-6
25. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*. 2018;39(2):119–77. <https://doi.org/10.1093/eurheartj/ehx393>
26. Massberg S, Polzin A. Update ESC-Leitlinie 2017: Duale Antiplättchentherapie Stand der Dinge Risikostratifizierung der DAPT Duale Plättchenhemmung nach elektiver koronarer Stentimplantation Duale Plättchenhemmung nach Stentimplantation im Rahmen eines akuten Koronarsyndroms. *DMW - Dtsch Medizinische Wochenschrift*. 2018;1090–3.
27. Scheen AJ. From atherosclerosis to atherothrombosis: From a silent chronic pathology to an acute critical event. *Rev Med Liege*. 2018;73(5–6):224–8.
28. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, et al. Hyperglycemia and acute coronary syndrome: A scientific statement from the american heart association diabetes committee of the council on nutrition, physical activity, and metabolism. *Circulation*. 2008;117(12):1610–9. <https://doi.org/10.1161/CIRCULATIONAHA.107.188629>
29. Monnier L, Colette C. Target for glycemic control: concentrating on glucose. *Diabetes Care*. 2009;32 Suppl 2. <https://doi.org/10.2337/dc09-s310>
30. Blonde L, Brunton SA, Chava P, Zhou R, Meyers J, Davis KL, et al. Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice. *Spectr DIABETES J*. 2018;32(2):93–103. <https://doi.org/10.2337/ds17-0082/-/DC1>



ichuthai N, Abdul-Ghani M, Kosiborod M, Parksook WW, Kerr SJ, Fronzo RA. Newly discovered abnormal glucose tolerance in patients with acute myocardial infarction and cardiovascular outcomes: A meta-analysis.

- Diabetes Care. 2020;43(8):1958–66. <https://doi.org/10.2337/dc20-0059>
32. Khawaja O, Bartz TM, H J, Heckbert SR, Kizer JR, Zieman SJ, et al. Plasma Free Fatty Acids and Risk of Atrial Fibrillation (From the Cardiovascular Health Study). *Am J Cardiol.* 2012;110(2):1–7. <https://doi.org/10.1016/j.amjcard.2012.03.010>. Plasma
 33. Zarich SW, Nesto RW. Implications and treatment of acute hyperglycemia in the setting of acute myocardial infarction. *Circulation.* 2007;115(18):436–9. <https://doi.org/10.1161/CIRCULATIONAHA.105.535732>
 34. Sethi SS, Akl EG, Farkouh ME. Diabetes mellitus and acute coronary syndrome: Lessons from randomized clinical trials. *Curr Diab Rep.* 2012;12(3):294–304. <https://doi.org/10.1007/s11892-012-0272-9>
 35. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. *Am J Cardiol.* 1972;30(6):595–602. [https://doi.org/10.1016/0002-9149\(72\)90595-4](https://doi.org/10.1016/0002-9149(72)90595-4)
 36. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 diabetes mellitus and heart failure a scientific statement from the American Heart Association and the Heart Failure Society of America. Vol. 140, *Circulation.* 2019. 294–324 p. <https://doi.org/10.1161/CIR.0000000000000691>
 37. Agarwal G, Singh S. Arrhythmias in type 2 diabetes mellitus. *Indian J Endocrinol Metab.* 2017;21(5):715–8. https://doi.org/10.4103/ijem.IJEM_448_16
 38. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, Incidence, Prognosis, and Predisposing Conditions for Atrial Fibrillation: Population-Based Estimates. *Am J Cardiol.* 1998;82(7 A):2N-9N. [https://doi.org/10.1016/s0002-9149\(98\)00583-9](https://doi.org/10.1016/s0002-9149(98)00583-9)
 39. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf P. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. *JAMA.* 1994;271(11):1051–5. <https://doi.org/10.1001/jama.1994.02910110105105>
 39. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial



fibrillation in the general male population: Morbidity and risk factors. *J Intern Med.* 2001;250(5):382–9. <https://doi.org/10.1046/j.1365-2796.2001.00902.x>

41. Nasution SA, Alwi I, Subekti I, Yamin M, Suhendro, Harimurti K, et al. The Role of Acute Hyperglycemia on the Risk of Malignant Arrhythmia in Acute Myocardial Infarction Patients: A Study of Myocardial Damage, Ion Channel Changes and Inflammatory Factors. *Acta Med Indones.* 2020;52(2):102–10.
42. Movahed MR, Hashemzadeh M, Mazen Jamal M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. *Int J Cardiol.* 2005;105(3):315–8. <https://doi.org/10.1016/j.ijcard.2005.02.050>
43. Tran H V., Gore JM, Darling CE, Ash AS, Kiefe CI, Goldberg RJ. Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction. *Cardiovasc Diabetol* [Internet]. 2018;17(1):1–9. Available from: <https://doi.org/10.1186/s12933-018-0779-8> doi: 10.1186/s12933-018-0779-8
44. Trongtorsak A, Kewcharoen J, Thangjui S, Yanez-Bello MA, Sous M, Prasai P, et al. Admission hyperglycemia in acute myocardial infarction is associated with an increased risk of arrhythmias: A systematic review and meta-analysis. *J Arrhythmia.* 2022;38(3):307–15. <https://doi.org/10.1002/joa3.12708>
45. Cheng SY, Wang H, Lin SH, Wen JH, Ma LL, Dai XC. Association of admission hyperglycemia and all-cause mortality in acute myocardial infarction with percutaneous coronary intervention: A dose–response meta-analysis. *Front Cardiovasc Med.* 2022;9(September):1–15. <https://doi.org/10.3389/fcvm.2022.932716>
46. Sari RP, Widyatmoko A. Kadar Glukosa Darah pada Penderita Infark Miokard Akut dengan Diabetes Melitus sebagai Faktor Prediktor Kematian. *Mutiara Med.* 2011;Vol.12 No.:72–8.



47. Barsheshet A, Garty M, Grossman E, Sandach A, Lewis BS, Gottlieb S, et al. Admission blood glucose level and mortality among hospitalized nondiabetic patients with heart failure. *Arch Intern Med*. 2006;166(15):1613–9. <https://doi.org/10.1001/archinte.166.15.1613>
48. Newton JD, Squire IB. Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure. *Heart*. 2006;92(10):1441–6. <https://doi.org/10.1136/hrt.2005.080895>
49. Ritsinger V, Hagström E, Lagerqvist B, Norhammar A. Admission glucose levels and associated risk for heart failure after myocardial infarction in patients without diabetes. *J Am Heart Assoc*. 2021;10(22). <https://doi.org/10.1161/JAHA.121.022667>
50. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? *J Am Coll Cardiol* [Internet]. 2002;40(10):1748–54. Available from: [http://dx.doi.org/10.1016/S0735-1097\(02\)02483-X](http://dx.doi.org/10.1016/S0735-1097(02)02483-X) doi: 10.1016/S0735-1097(02)02483-X
51. Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. *Circulation*. 2007;115(11):1371–5. <https://doi.org/10.1161/CIRCULATIONAHA.106.661405>
52. Schainberg A, Ribeiro-Oliveira A, Ribeiro JM. Is there a link between glucose levels and heart failure? An update. *Arq Bras Endocrinol Metabol*. 2010;54(5):488–97. <https://doi.org/10.1590/s0004-27302010000500010>
53. Benamer S, Eljazwi I, Mohamed R, Masoud H, Tuwati M, Elbarsha AM. Association of hyperglycemia with in-hospital mortality and morbidity in Libyan patients with diabetes and acute coronary syndromes. *Oman Med J*. 2015;30(5):326–30. <https://doi.org/10.5001/omj.2015.67>
54. Abdel H Ahmed, Sinclair J Alan. Low HbA1c and increased mortality risk frailty a cofounding factor. *Aging and Disease*. 2015; 6(4):262-270. [ps://doi.org/10.14336/AD.2014.1022](https://doi.org/10.14336/AD.2014.1022)
 imos B, Mahfoud Z, Dargham S, Al Suwaidi J, Jneid H, Abi Khalil C.



Hypoglycemia is associated with a higher risk of mortality and arrhythmias in ST-elevation myocardial infarction, irrespective of diabetes. *Front Cardiovasc Med.* 2022;9 (October).
<https://doi.org/10.3389/fcvm.2022.940035>

56. Salarifar M, Sadeghian S, Darabyan S, Solaymani A, Amirzadegan AR, Mahmoudian M, et al. Factors affecting in-hospital mortality of acute myocardial infarction. *Iran J Public Health.* 2009;38(3):97–104.

